Table 3.
Treatment for the two study groups.
| Variable | Total patients (n = 314) | Epi group (n = 107) | Non-epi group (n = 204) | p-value |
|---|---|---|---|---|
| Medical treatment | ||||
| Epinephrine-no. (%) | 107 (34.1) | 107 (100) | 0 (0) | – |
| Delayed use of epinephrine-no. (%) | 27 (8.6) | 27 (25.2) | 0 (0) | – |
| Repeated use of epinephrine-no. (%) | 18 (5.7) | 12 (16.8) | 0 (0) | – |
| Steroids-no. (%) | 307 (97.8) | 105 (98.1) | 202 (97.6) | 0.76 |
| H1 blockers (antihistamines)-no. (%) | 310 (98.7) | 105 (98.1) | 205 (99.0) | 0.50 |
| H2 blockers-no. (%)a | 24 (7.6) | 8 (7.5) | 16 (7.7) | 0.94 |
| Beta-agonist nebulizer-no. (%) | 51 (16.2) | 14 (13.1) | 37 (17.9) | 0.28 |
| Other inotropic agents-no. (%)a | 13 (4.1) | 11 (10.2) | 2 (0.9) | <0.01* |
| ED supportive care | ||||
| O2 supplementation-no. (%)a | ||||
| Intubation-no. (%)a | 2 (0.6) | 2 (1.9) | 0 (0.0) | 0.12 |
| Fluid challenge-no. (%) | 156 (49.7) | 69 (64.5) | 87 (42.0) | <0.01* |
| Bed rest-no. (%) | 299 (95.2) | 103 (96.3) | 196 (94.7) | 0.54 |
| Monitoring-no. (%) | 284 (90.5) | 98 (91.6) | 186 (89.9) | 0.62 |
IV, intravenous; IM, intramuscular. Data are expressed as numbers (%).
a
Fisher’s exact test *p < 0.05.